Get started
Author

Ying Cheng

Observed names: Cheng Ying, Cheng, Ying, Y. Cheng
ORCID: 0000-0002-1517-501X
Observed ORCID: 0000-0002-1517-501X
OpenAlex ID: A5101793086
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial
2018 · Baohui Han, Kai Li, et al. · JAMA Oncology · 633
PDF
Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
2020 · Ying Cheng, Baohui Han, et al. · Cancer Medicine · 36
PDF
The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial
2019 · Lili Wang, Zhen He, et al. · Translational Lung Cancer Research · 36
PDF
Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial
2021 · Ying Cheng, Qiming Wang, et al. · Cancer Medicine · 23
PDF
Precise identification of somatic and germline variants in the absence of matched normal samples
2024 · Hui Li, Lu Meng, et al. · Briefings in Bioinformatics · 11
PDF
P2.12-26 The Impact of Anlotinib for Relapsed SCLC Patients with Brain Metastases: A Subgroup Analysis of ALTER 1202
2019 · Y. Cheng, Q. Wang, et al. · Journal of Thoracic Oncology · 10
PDF
Acupuncture and/or moxibustion for the treatment of lumbar disc herniation: quality assessment of systematic reviews
2020 · ZiHan Yin, ChaoXi Zhu, et al. · Traditional Medicine Research · 8
Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: Preliminary results from a phase 2 study.
2025 · Li Zhang, Wenfeng Fang, et al. · Journal of Clinical Oncology · 7
PDF
123TiP: TROPION-Lung14: A phase III study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC)
2025 · S.B. Goldberg, M. Provencio Pulla, et al. · Journal of Thoracic Oncology · 6
PDF
Subgroup analysis of histology in ALTER0303: Anlotinib hydrochloride as 3rd line and further line treatment in refractory advanced NSCLC patients (pts).
2018 · Ying Cheng, Baohui Han, et al. · Journal of Clinical Oncology · 6
MA04.08 Perioperative Tislelizumab for Resectable Non-small Cell Lung Cancer: Final Analysis of RATIONALE-315
2025 · D. Yue, W. Wang, et al. · Journal of Thoracic Oncology · 5
Abstract CT126: Aumolertinib as adjuvant therapy in patients with stage II-IIIB EGFR-mutated NSCLC after complete tumor resection: A randomized, double-blind, placebo-controlled, phase 3 trial (ARTS)
2025 · Ying Cheng, Xiqin Zhang, et al. · Cancer Research · 4
OA03.02 Effect of Anlotinib in Advanced Small Cell Lung Cancer Patients Previously Received Chemoradiotherapy: A Subgroup Analysis in ALTER 1202 Trial
2019 · Q. Wang, Y. Cheng, et al. · Journal of Thoracic Oncology · 4
TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR -mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC).
2025 · Shun Lu, Mariano Provencio, et al. · Journal of Clinical Oncology · 3
Effect of SHR-1701 on chemotherapy (chemo)-induced myelosuppression: Data from a phase 3 study in HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA).
2025 · Zhi Peng, Jufeng Wang, et al. · Journal of Clinical Oncology · 3
1787P Effect of anlotinib in advanced small cell lung cancer patients with pleural metastases/pleural effusion: A subgroup analysis from a randomized, double-blind phase II trial (ALTER1202)
2020 · Y. Liu, Y. Cheng, et al. · Annals of Oncology · 3
MA08.06 Comparison of Asandeutertinib and Osimertinib in EGFR-Mutated NSCLC With Brain Metastases: Interim Analysis of the ESAONA Pivotal Study
2025 · Y. Shi, L. Xing, et al. · Journal of Thoracic Oncology · 2
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer
2024 · Zefei Jiang, Quchang Ouyang, et al. · Future Oncology · 1
PDF
P1.11.35 RATIONALE-303: Long-Term Outcomes With Tislelizumab in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
2025 · C. Zhou, Y. Fan, et al. · Journal of Thoracic Oncology
Abstract PS2-01: Dalpiciclib versus placebo in combination with letrozole or anastrozole as first-line treatment for women with HR+/HER2- advanced breast cancer: prespecified final analysis of progression-free survival of the phase 3 DAWNA-2 trial
2025 · Binghe Xu, Pin Zhang, et al. · Clinical Cancer Research
Abstract GS1-03: Pyrotinib or placebo in combination with trastuzumab and docetaxel for untreated HER2-positive metastatic breast cancer (mBC): prespecified final analysis of progression-free survival (PFS) of the phase 3 PHILA trial
2025 · Binghe Xu, Fei Ma, et al. · Clinical Cancer Research
439 | Analysis of a Phase 1 Study of Zanubrutinib + Lenalidomide in Patients With Relapsed/refractory Diffuse Large B‐cell Lymphoma
2025 · Z. Song, Y. Cheng, et al. · Hematological Oncology
PDF
EV103/#405 A phase I/II dose-escalation and efficacy/safety study of afuresertib plus sintilimab plus nab-paclitaxel in solid tumors primarily cervical cancer and endometrial cancer
2024 · Lin Shen, Rutie Yin, et al. · International Journal of Gynecological Cancer
PDF
Real-Time System Predictive Analysis for Heart Rate Pathologies using Machine Learning
2022 · Yu Wang, Ying Cheng, et al. · Thesis Commons (OSF Preprints)
Analysis on the Development of Intellectual Property Rights in Tianjin
2021 · Ying Cheng, Juanxia Zhao, et al. · Advances in Social Science, Education and Humanities Research/Advances in social science, education and humanities research
PDF
Works count: 27
Citation count: 801
H-index: 7
I10-index: 6
Year
Topic
Type